Downstream Issues Still Beset Production
To Protect the Bottom Line, Biomanufacturers Invest in Downstream Purification Technology
GEN Roundup: No Detail Is Too Small in Bioprocess Scaleup
A Change in Scale Can Change Everything
Amid Election Clamor, Research Issues Surface
Sounds of Science Podcast
10 Takeover Targets of 2016
Which Biopharmas Do Wall Street Watchers View As Top Buyout Candidates?
For full access to this article login to GEN Select now.
Engineering Regenerative Medicine's Future
Global Standards in Conjunction with Enabling Technologies Hold Key to Advancing the Field
- Stakeholders in the regenerative medicine sector recognize that the commercialization of novel therapeutic interventions faces a number of bottlenecks before these treatments can be adopted by existing healthcare providers. Since companies focused on regenerative medicine first attracted investment, many firms have identified opportunities and have set about attempting to ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.